Cited by 2,604Heart Failure Treatment and ManagementRenin-Angiotensin System StudiesHeart rate and cardiovascular health

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, John JV, Östergren, Jan, Swedberg, Karl, Granger, Christopher B, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Yusuf, Salim, Pfeffer, Marc A·2003·The Lancet

DOI 10.1016/s0140-6736(03)14283-3

Open this paper in CoChat — free account

Abstract

Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat.Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment.Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14283-3

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,993
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citation
The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis
Cleland, J. G. F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,553
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,440
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194

Show all 38 references

Sorted by citations

Items 801–900 of 1,001

Quality of Life and Antihypertensive Drug Therapy
Handler, J. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04470.x · Cited by 28
Current Challenges in the Management of Heart Failure
Michel Komajda, N. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0368 · Cited by 27
Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement
Rosendorff, C., Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.045 · Cited by 30
Foundation/American Heart Association Task Force on Practice Guidelines Heart Failure in Adults. A Report of the American College of Cardiology Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of
Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Abraham, W. T., Casey, D. E., Feldman, A. M., & Ma, G. S. (2009) · Cited by 27
Kicking the Tyres of a Heart Failure Trial: Physician Response to the Approval of Sacubitril/valsartan in the USA
Packer, M. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.623 · Cited by 27
Aliskiren Alone or in Combination with Enalapril vs. Enalapril Among Patients with Chronic Heart Failure with and without Diabetes: A Subgroup Analysis from the ATMOSPHERE Trial
Kristensen, S. L., Mogensen, U. M., Tarnesby, G., Gimpelewicz, C. R., Ali, M. A., Shao, Q., Chiang, Y., Jhund, P. S., Abraham, W. T., Dickstein, K., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.896 · Cited by 27
Self-citation
“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
Simpson, J., Benson, L., Jhund, P. S., Dahlström, U., McMurray, J. J. V., & Lund, L. H. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06873-1 · Cited by 27
Self-citation
Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?
Raffaello, W. M., Henrina, J., Huang, I., Lim, M. A., Suciadi, L. P., Siswanto, B. B., & Pranata, R. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.20 · Cited by 30
Congestive heart failure in Indians: How do we improve diagnosis & management?
Sreenivas Reddy, S., Bahl, A., & Talwar, K. K. (2010) · The Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_549 · Cited by 27
Renin Angiotensin System and Cardiovascular Disease
DEMELLO, W., & Frohlich, E. D. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-186-8 · Cited by 27
The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program
Pocock, S., Wang, D., Wilhelmsen, L., & Hennekens, C. H. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.038 · Cited by 27
Partial Peroxisome Proliferator-Activated Receptor Agonist Angiotensin Receptor Blockers
Towfighi, A., & Ovbiagele, B. I. (2008) · Cerebrovascular Diseases · doi:10.1159/000139656 · Cited by 27
Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly
Jugdutt, B. I. (2008) · Heart Failure Reviews · doi:10.1007/s10741-008-9090-1 · Cited by 27
Valsartan in the treatment of heart attack survivors
Jugdutt, B. I. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.2.125 · Cited by 27
Comparing angiotensin II receptor blockers on benefits beyond blood pressure
Siragy, H. M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0028-3 · Cited by 27
Activation of Thiazide-Sensitive Co-Transport by Angiotensin II in the cyp1a1-Ren2 Hypertensive Rat
Ashek, A., Menzies, R. I., Mullins, L. J., Bellamy, C. O. C., Harmar, A. J., Kenyon, C. J., Flatman, P. W., Mullins, J. J., & Bailey, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036311 · Cited by 27
Olmesartan Medoxomil–Induced Angioedema
Nykamp, D. L., & Winter, E. E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h566 · Cited by 27
Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: A meta-analysis of >35,000 patients
Peck, K. Y., Lim, Y. Z., Hopper, I., & Krum, H. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.014 · Cited by 27
Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Bax, J. J., Borger, M. A., Chew, D. P., Hasenfuss, G. P., Kjeldsen, K. P., et al. (2015) · Cited by 27
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8 · Cited by 28
Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy
Jacobsen, P. K., Rossing, K., & Parving, H. (2004) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200405000-00009 · Cited by 27
The role of renin–angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
Karagiannis, A. I., Mikhailidis, D. P., Athyros, V. G., Kakafika, A. I., Τζιόμαλος, Κ., Liberopoulos, E. N., Florentin, M., & Elisaf, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.191 · Cited by 28
Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin–angiotensin system
Hošková, L., Málek, I., Kautzner, J., Honsová, E., van Dokkum, R. P. E., Husková, Z., Vojtíšková, A., Jíchová, Š., Červenka, L., & Kopkan, L. (2014) · Hypertension Research · doi:10.1038/hr.2014.79 · Cited by 29
Patient Perception of the Effect of Treatment with Candesartan in Heart Failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
O’Meara, E., Lewis, E. F., Granger, C. B., Dunlap, M. E., McKelvie, R. S., Probstfield, J. L., Young, J. B., Michelson, E. L., Östergren, J., Carlsson, J., et al. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.021 · Cited by 27
Self-citation
Recent changes in the landscape of combination RAS blockade
Epstein, B. J., Smith, S. M., & Choksi, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.127 · Cited by 27
Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor
Costa‐Scharplatz, M., van Asselt, A. D. I., Bachmann, L. M., Kessels, A. G. H., & Severens, J. L. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000236336.34175.e8 · Cited by 27
Targeting effective blood pressure control with angiotensin receptor blockers
Asmar, R. G. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00784.x · Cited by 27
ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation
Sobhy, M. A., Eletriby, A., Ragy, H. I., Kandil, H., Saleh, M. A., Farag, N. M., Guindy, R. R., Bendary, A., Nayel, A. E. M., Shawky, A., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00381-6 · Cited by 28
Renin–Angiotensin System Blockade in Heart Failure Patients on Long-Term Haemodialysis in Taiwan
Tang, C., Chen, T., Wang, C., Hong, C., Huang, K., & Sue, Y. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft082 · Cited by 26
El autocuidado y el conocimiento del manejo de la enfermedad predicen la rehospitalización en ancianos con insuficiencia cardíaca
Rodríguez‐Artalejo, F., Guallar‐Castillón, P., Otero, C. M., Herrera, M. C., Carreño, C., Martín, A. I. T., Olcoz‐Chiva, M., Conthe, P., Banegas, J. R., & Pascual, C. (2008) · Revista Clínica Española · doi:10.1157/13123185 · Cited by 26
Evidence-Based Therapy for Heart Failure
DEEDWANIA, P. C., & Carbajal, E. V. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.010 · Cited by 26
Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors
Kanasaki, M., Nagai, T., Kitada, M., Koya, D., & Kanasaki, K. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-25 · Cited by 26
The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review
Shibata, M. C., Tsuyuki, R. T., & Wiebe, N. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01806.x · Cited by 26
Which, if any, antihypertensive agents cause cancer?
Singh, A., & Bangalore, S. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353bc4f · Cited by 26
New Bundled World: Quality of Care and Readmission in Diabetes Patients
Chen, J. Y., Ma, Q., Chen, H., & Yermilov, I. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600311 · Cited by 26
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
Jugdutt, B. I. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6709 · Cited by 26
An update of the blockade of the renin angiotensin aldosterone system in clinical practice
Márquez, D. F., Ruiz‐Hurtado, G., Ruilope, L. M., & Segura, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1079623 · Cited by 26
Expert Comment: Is Medication Titration in Heart Failure too Complex?
Atherton, J. J., & Hickey, A. (2017) · Cardiac failure review · doi:10.15420/cfr.2017:1:2 · Cited by 26
Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence
Tsouli, S. G., Liberopoulos, E. N., Kiortsis, D. N., Mikhailidis, D. P., & Elisaf, M. (2006) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840601100101 · Cited by 26
The implications of a growing evidence base for drug use in elderly patients Part 2 − ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients
Mangoni, A. A., & Jackson, S. H. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02610.x · Cited by 26
Combination Angiotensin‐Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice
Sica, D. A. (2003) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2003.02836.x · Cited by 26
Future Pharmacologic Agents for Treatment of Heart Failure in Children
Moffett, B. S., & Chang, A. C. (2006) · Pediatric Cardiology · doi:10.1007/s00246-006-1289-0 · Cited by 26
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 26
Medical Therapy Leads to Favorable Remodeling in Left Ventricular Non-compaction Cardiomyopathy: Dilated Phenotype
Parent, J. J., Towbin, J. A., & Jefferies, J. L. (2016) · Pediatric Cardiology · doi:10.1007/s00246-015-1330-2 · Cited by 25
Guideline-directed medical therapy in heart failure patients: impact of focused care provided by a heart failure clinic in comparison to general cardiology out-patient department
Joseph, J., Stephy, P. S., James, J., Abraham, S., & Abdullakutty, J. (2020) · The Egyptian Heart Journal · doi:10.1186/s43044-020-00088-8 · Cited by 25
Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report
Brinkley, D. M., Wang, L., Yu, C., Grandin, E. W., & Kiernan, M. S. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.08.015 · Cited by 26
Cardiovascular Research in Friedreich Ataxia
Payne, R. M. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.005 · Cited by 25
Inhibition of Renin-Angiotensin System: Implications for Diabetes Control and Prevention
Prabhakar, S. S. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31828298ce · Cited by 25
Vascularisation for cardiac tissue engineering: the extracellular matrix
Patra, C., Boccaccini, A. R., & Engel, F. B. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0480 · Cited by 25
Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition
Segura, J., Salazar, J. B., & Ruilope, L. M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.797962 · Cited by 25
Neurohumoral Effects of Aliskiren in Patients with Symptomatic Heart Failure Receiving a Mineralocorticoid Receptor Antagonist: The Aliskiren Observation of Heart Failure Treatment Study
Pitt, B., Latini, R., Maggioni, A. P., Solomon, S. D., Smith, B. A., Wright, M., PRESCOTT, M. F., & McMurray, J. J. V. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr034 · Cited by 25
Self-citation
Heart Failure in the Elderly
Forman, D. E., & Rich, M. W. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2003.00798.x · Cited by 25
Pharmacologic Therapy of Chronic Heart Failure
Hamad, E., Mather, P. J., Srinivasan, S., Rubin, S., Whellan, D. J., & Feldman, A. M. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707040-00002 · Cited by 25
Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines
Frisk, P., Mellgren, T.-O., Hedberg, N., Berlin, A., Granath, F. N., & Wettermark, B. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0495-5 · Cited by 25
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model
Dai, Z., Yu, S., Zhao, Q., Meng, Y., Huang, H., Tang, Y., Wang, X., Xiao, J., Wang, X., & Huang, C. (2014) · EuroIntervention · doi:10.4244/eijv10i3a65 · Cited by 25
The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line
Miura, S., Suematsu, Y., Matsuo, Y., Tomita, S., Nakayama, A., Goto, M., Arimura, T., Kuwano, T., Yahiro, E., & Saku, K. (2016) · Hypertension Research · doi:10.1038/hr.2016.72 · Cited by 25
Losartan Attenuates Scar Formation in Filtering Bleb After Trabeculectomy
Shi, H., Wang, H., Fu, S., Xu, K., Zhang, X., Xiao, Y., & Ye, W. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-21163 · Cited by 25
Oedema‐fibrosis in Duchenne Muscular Dystrophy: Role of cardiovascular magnetic resonance imaging
Mavrogeni, S. I., Papavasiliou, A., Giannakopoulou, K., Markousis‐Mavrogenis, G., Pons, M. R., Karanasios, E., Nikas, I., Papadopoulos, G., Kolovou, G. D., & Chrousos, G. P. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12843 · Cited by 25
Days alive out of hospital in heart failure: Insights from the PARADIGM-HF and CHARM trials
Chen, Y., Lawrence, J., & Stockbridge, N. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.03.016 · Cited by 25
Klinische Kardiologie
(2011) · Springer eBooks · doi:10.1007/978-3-642-16481-1 · Cited by 25
Improvement in prognosis of dilated cardiomyopathy in the elderly over the past 20 years
Kubo, T., Matsumura, Y., Kitaoka, H., Okawa, M., Hirota, T., Hamada, T., Hitomi, N., Hoshikawa, E., Hayato, K., Shimizu, Y., et al. (2008) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.06.001 · Cited by 25
Rationale for the Use of Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Therapy in Heart Failure
Yasumura, Y., Miyatake, K., Okamoto, H., Miyauchi, T., Kawana, M., Tsutamoto, T., Kitakaze, M., Matsubara, H., Takaoka, H., Anzai, T., et al. (2004) · Circulation Journal · doi:10.1253/circj.68.361 · Cited by 25
Role of the Renin-Angiotensin-Aldosterone System in Diastolic Heart Failure
Bernal, J., Pitta, S. R., & Thatai, D. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606060-00004 · Cited by 25
Latin American consensus on diabetes mellitus and hypertension
Burlando, G., nchez, R. A. S., Ramos, F. H., Mogensen, C. E., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00001 · Cited by 25
Best practice in primary care pathology: review 6: Figure 1
Smellie, W. S. A., Forth, J., Coleman, J. J., Irvine, W., Dore, P. C., Handley, G., Williams, D., Galloway, P., Kerr, K. G., Herriot, R., et al. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040014 · Cited by 25
2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure.
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 24
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients
Hasegawa, H., Takano, H., Narumi, H., Ohtsuka, M., Mizuguchi, T., Namiki, T., Kobayashi, Y., & Komuro, I. (2011) · Hypertension Research · doi:10.1038/hr.2011.114 · Cited by 24
Contemporary Medical Management of Systolic Heart Failure
Nair, A. P., Timoh, T., & Fuster, V. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1424 · Cited by 24
Unbelievable Folly of Clinical Trials in Heart Failure
Packer, M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.002837 · Cited by 24
Pharmacology of heart failure: From basic science to novel therapies
Lother, A., & Hein, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.004 · Cited by 24
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME
Böhm, M., Fitchett, D., Ofstad, A. P., Brueckmann, M., Kaspers, S., George, J. T., Zwiener, I., Zinman, B., Wanner, C., Marx, N., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002492 · Cited by 24
Optimal effectiveness of heart failure management — an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure
Hafkamp, F. J., Tio, R. A., Otterspoor, L., Greef, T. V.-D., van Steenbergen, G. J., van de Ven, A. R. T., Smits, G., Post, H., & van Veghel, D. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10212-8 · Cited by 24
20 Years of Real-World Data to Estimate the Prevalence of Heart Failure and Its Subtypes in an Unselected Population of Integrated Care Units
Gavina, C., Seabra, D., Valente, F., Bernardo, F., Dinis‐Oliveira, R. J., Santos-Araújo, C., & Taveira‐Gomes, T. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050149 · Cited by 24
ACE Inhibitors in Heart Failure
Demers, C., Mody, A., Teo, K. K., & McKelvie, R. S. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00002 · Cited by 24
Results of the ONTARGET and TRANSCEND studies: an update and discussion
Fitchett, D. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3718 · Cited by 24
Treatment of isolated systolic hypertension in the elderly
Duprez, D. A. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.117 · Cited by 24
Current Pharmacological Therapies in Heart Failure Patients
Muiesan, M. L., Paini, A., Rosei, C. A., Bertacchini, F., Stassaldi, D., & Salvetti, M. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0194-3 · Cited by 24
Seventeen-Year Nationwide Trends in Antihypertensive Drug Use in Denmark
Sundbøll, J., Adelborg, K., Mansfield, K. E., Tomlinson, L. A., & Schmidt, M. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.08.042 · Cited by 24
Contemporary Management of Heart Failure in the Elderly
Osmanska, J., & Jhund, P. S. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0625-4 · Cited by 26
Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting
Gonçalves, C. B. C., Moreira, L. B., Gus, M., & Fuchs, F. D. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0352-y · Cited by 24
Inhibiting the renin–angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials
Tokmakova, M. P., & Solomon, S. D. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231394.79609.24 · Cited by 24
Update on the Management of Hypertension: Recent Clinical Trials and the JNC 7
Moser, M. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03830.x · Cited by 24
Exposure of the elderly to potential nephrotoxic drug combinations in Belgium
Smets, H. L., Haes, J. F. D., Swaef, A. D., Jorens, P. G., & Verpooten, G. A. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1641 · Cited by 24
Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure
Funabiki, K., Onishi, K., Dohi, K., Koji, T., Imanaka‐Yoshida, K., Ito, M., Wada, H., Isaka, N., Nobori, T., & Nakano, T. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00462.2004 · Cited by 24
Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide
Chrysant, S. G., & Chrysant, G. S. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.3.657 · Cited by 24
ARBs and target organ protection
Silverstein, R. L., Fenves, A. Z., & Ram, C. V. S. (2004) · Postgraduate Medicine · doi:10.3810/pgm.2004.08.1569 · Cited by 24
The renin angiotensin system as a therapeutic target to prevent diabetes and its complications
Vijayaraghavan, K., & DEEDWANIA, P. C. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.11.003 · Cited by 24
Challenges in improving prognosis and therapy: The Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial Programme
Zimmermann, M., & Unger, T. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.5.1201 · Cited by 24
Serum potassium and heart failure: association, causation, and clinical implications
Sfairopoulos, D., Arseniou, A., & Korantzopoulos, P. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10039-9 · Cited by 23
Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients
Wetmore, J. B., Mahnken, J. D., Mukhopadhyay, P., Hou, Q., Ellerbeck, E. F., Rigler, S. K., Spertus, J. A., & Shireman, T. I. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.02.387 · Cited by 24
Impact of insulin therapy on the mortality of acute heart failure patients with diabetes mellitus
Jang, S. Y., Jang, J., Yang, D. H., Cho, H., Lim, S. K., Jeon, E., Lee, S. E., Kim, J., Kang, S., Baek, S. H., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01370-y · Cited by 23
Angiotensin-Converting Enzyme and Heart Failure
Álvarez-Zaballos, S., & Martínez‐Sellés, M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807150 · Cited by 26
Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism
Poggio, R., Grancelli, H., & Miriuka, S. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.072058 · Cited by 23
Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease
Frimodt‐Møller, M., Nielsen, A. H., Strandgaard, S., & Kamper, A. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp547 · Cited by 23
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
Dézsi, C. A., & Szentes, V. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0185-0 · Cited by 23
Impact of an antimicrobial stewardship programme on antibiotic usage and resistance in a tertiary hospital in China
Zhang, Z.-G., Chen, F., & Ou, Y. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12544 · Cited by 23
Treatment of Hyperkalemia in Heart Failure
DeFilippis, E. M., & Desai, A. S. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0341-0 · Cited by 23
Sympathetic activation and outcomes in chronic heart failure: Does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients?
Jiménez‐Marrero, S., Moliner, P., Rodríguez-Costoya, I., Enjuanes, C., Alcoberro, L., Yun, S., González‐Costello, J., Garay, A., Tajes, M., Calero, E., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.008 · Cited by 23
Telmisartan Reduces Mortality and Left Ventricular Hypertrophy With Sympathoinhibition in Rats with Hypertension and Heart Failure
Kishi, T., Hirooka, Y., & Sunagawa, K. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt188 · Cited by 23
Adherence to Guidelines Is a Predictor of Outcome in Chronic Heart Failure: The MAHLER Survey
Michel Komajda, N., Lapuerta, P., & Hermans, N. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.11.040 · Cited by 23

Authors: McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A.
Affiliations: University of Glasgow (GB)
Karolinska University Hospital (SE)
Sahlgrenska University Hospital (SE)
Duke Medical Center (US)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)
Hamilton Health Sciences (CA)
Brigham and Women's Hospital (US)
Corresponding author: McMurray, John JV
ORCID: McMurray, John JV
Östergren, Jan
Swedberg, Karl
Granger, Christopher B
Yusuf, Salim
Pfeffer, Marc A
Venue: The Lancet
Publisher: Elsevier BV
Published: 2003-09
Volume: 362
Issue: 9386
Pages: 767-771
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(03)14283-3
OpenAlex: W2098780362
Cited by: 2,604
References: 38
Citations by year: 2026: 8 · 2025: 15 · 2024: 46 · 2023: 52 · 2022: 58 · 2021: 60 · 2020: 98 · 2019: 82 · 2018: 66 · 2017: 103 · 2016: 108 · 2015: 118 · 2014: 122 · 2013: 126 · 2012: 153
FWCI: 122.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords: candesartan, chronic heart failure, reduced left ventricular ejection fraction, angiotensin receptor blockers, ACE inhibitors, combination therapy, cardiovascular mortality, beta-blockers, spironolactone
MeSH terms: Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Cardiac Output, Low, Cardiovascular Diseases, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Placebos, Tetrazoles, Comorbidity, Treatment Outcome, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks